Obadia Mfuh Kenji joined Stanford after the pandemic's first surge in May 2020, overcoming challenges to help deploy COVID-19 testing.
Stanford researchers have found a good drug target for treating Diamond-Blackfan anemia, a genetic disease that impairs red blood cell formation.
Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.
How exactly does the antiviral drug remdesivir counter SARS-CoV-2 – the coronavirus strain responsible for COVID-19? And how well?
A Stanford microbiologist describes the invigorating, yet sobering race to develop an effective vaccine against COVID-19.
The Innovative Medicines Accelerator builds on existing programs at Stanford — but fills in gaps to help researchers turn ideas into drugs.
A study provides evidence that the drug azlocillin eliminates the bacteria that cause Lyme disease at the onset of infection in lab mice and cultures.
Most children with antibiotic-resistant urinary tract infections get better on less powerful antibiotics than lab tests say they need, says Stanford study.
Hundreds of Stanford scientists are studying what makes biology tick, from obscure molecular structures in the malaria parasite to flower-shaped sea squirts.
The parasite that causes malaria is remarkably adept at developing resistance to the drugs devised to combat it. But new research suggests a solution.
At a recent Dean's Lecture Series, Dean Lloyd Minor discussed organizational culture and diversity with Emma Walmsley, CEO of GlaxoSmithKline.
An antibody against the "don't eat me" signal on cancer cells appears safe and well-tolerated by patients with advanced cancers. A phase 2 trial is planned.
Patients who are taking the most common type of antidepressant may feel more pain when taking certain opioids, Stanford researchers have found.
Stanford researchers have discovered a compound that reduces the symptoms of heart failure after a heart attack in initial animal tests.
A Stanford professor unpacks some of the dynamics of the current drug pricing system and the potential effects of other approaches to this market.
Stanford chemists have developed a potential new strategy for fighting antibiotic-resistant bacterium — adding a new molecule onto an existing antibiotic.
